Fulminant Hepatitis during Treatment with Propylthiouracil

Publisher Website
Google Scholar
Abstract
THE effectiveness and relative lack of toxicity of propylthiouracil have made it valuable in the treatment of thyrotoxicosis. Untoward reactions, especially granulocytopenia, rarely hepatic injury, were encountered frequently with its predecessor, thiouracil. However, hematologic changes with propylthiouracil have proved so unusual that some clinicians consider periodic blood counts an unnecessary precaution during therapy.1 Abandonment of such a safeguard is to be decried since other authors2 3 4 report as high as a 2 to 4 per cent incidence of toxic reactions with propylthiouracil. In 1651 treated cases granulocytopenia occurred in 19.4 The literature contains several reports of liver damage in patients receiving . . .